Bediako-Bowan AAA, Naalane N, Dakubo JCB. Morbidity and oncological outcomes after intersphincteric resection of the rectum for low-lying rectal cancer: experience of a single center in a lower-middle-income country. BMC Surg. 2023;23(1):39. https://doi.org/10.1186/s12893-023-01940-9.

Article  PubMed  PubMed Central  Google Scholar 

Schrag D, Qian Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389(4):322–34. https://doi.org/10.1056/NEJMoa2303269.

Article  CAS  Google Scholar 

Gevorkyan YA, Soldatkina NV, Chernyak MN, Gusareva MA, Bondarenko OK, Jenkova EA, et al. A new method of modified chemotherapy for cancer of the upper and middle ampullary rectum. South Russian Journal of Oncology. 2023;4(2):56–63. https://doi.org/10.37748/2686-9039-2023-4-2-6, https://elibrary.ru/etddql.

Dobrodeev AY, Afanasyev SG, Tarasova AS, Kostromitsky DN, Avgustinovich AV, Frolova IG, et al. Short-term outcomes of preoperative chemotherapy in patients with upper ampullary rectal cancer. Sib J Oncol. 2021;20(6):23–31. https://doi.org/10.21294/1814-4861-2021-20-6-23-31.

Article  Google Scholar 

Szilágyi M, Pös O, Márton É, Buglyó G, Soltész B, Keserű J, Penyige A, Szemes T, Nagy B. Circulating cell-free nucleic acids: main characteristics and clinical application. Int J Mol Sci. 2020;21(18):6827. https://doi.org/10.3390/ijms21186827.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11(1):3475. https://doi.org/10.1038/s41467-020-17316-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: implications for diagnosis and therapy. Oncol Lett. 2018;16(1):9–18. https://doi.org/10.3892/ol.2018.8679.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai X, Ren T, Zhang Y, Nan N. Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021;23(e2):1–10. https://doi.org/10.1017/erm.2021.4.

Article  CAS  Google Scholar 

Ehrlich M. DNA hypermethylation in disease: mechanisms and clinical relevance. Epigenetics. 2019;14(12):1141–63. https://doi.org/10.1080/15592294.2019.1638701.

Article  PubMed  PubMed Central  Google Scholar 

Ghadiri Moghaddam F, Farajnia S, Karbalaei-Mahdi M, Monir L. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review. Mol Biol Rep. 2022;49(10):10013–22. https://doi.org/10.1007/s11033-022-07569-w.

Article  CAS  PubMed  Google Scholar 

Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, Fung KYC, Ross JP. DNA methylation cancer biomarkers: translation to the clinic. Front Genet. 2019;10:1150. https://doi.org/10.3389/fgene.2019.01150.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer. 2014;14:54. https://doi.org/10.1186/1471-2407-14-54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedersen SK, Mitchell SM, Graham LD, McEvoy A, Thomas ML, Baker RT, et al. CAHM, a long non-coding RNA gene hypermethylated in colorectal neoplasia. Epigenetics. 2014;9(8):1071–82. https://doi.org/10.4161/epi.29046.

Article  PubMed  PubMed Central  Google Scholar 

Pedersen SK, Symonds EL, Baker RT, Murray DH, McEvoy A, Van Doorn SC, et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015;15:654. https://doi.org/10.1186/s12885-015-1674-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu P, Zhu X, Song Y, Luo Y, Lin J, Zhang J, et al. Methylated Septin 9 as a promising biomarker in the diagnosis and recurrence monitoring of colorectal cancer. Dis Markers. 2022;2022:7087885. https://doi.org/10.1155/2022/7087885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S, et al. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019;19(1):450. https://doi.org/10.1186/s12885-019-5663-8.

Article  PubMed  PubMed Central  Google Scholar 

Sun J, Xu J, Sun C, Zheng M, Li Y, Zhu S, Zhang S. Screening and prognostic value of methylated Septin9 and its association with clinicopathological and molecular characteristics in colorectal cancer. Front Mol Biosci. 2021;8. https://doi.org/10.3389/fmolb.2021.568818.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Hu B, Gui YC, Tan ZB, Xu JW. Diagnostic Value and clinical significance of methylated SEPT9 for colorectal cancer: a meta-analysis. Med Sci Monit. 2019;25:5813–22. https://doi.org/10.12659/MSM.915472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang M, He J, Lai W, Liu L, Xu H, Zeng Y, et al. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery. BMC Gastroenterol. 2022;22(1):87. https://doi.org/10.1186/s12876-022-02172-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Z, Wang S, Ni K, Zhan Y, Ma H, Liu X, et al. Circulating methylated SEPT9 DNA analyses to predict recurrence risk and adjuvant chemotherapy benefit in stage II to III colorectal cancer. Med Sci Monit. 2022;28:e937757. https://doi.org/10.12659/MSM.937757.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jedi M, Young GP, Pedersen SK, Symonds EL. Methylation and gene expression of BCAT1 and IKZF1 in colorectal cancer tissues. Clin Med Insights Oncol. 2018;12:1179554918775064. https://doi.org/10.1177/1179554918775064.

Article  PubMed  PubMed Central  Google Scholar 

Nassar FJ, Msheik ZS, Nasr RR, Temraz SN. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction. Clin Epigenetics. 2021;13(1):111. https://doi.org/10.1186/s13148-021-01095-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kong C, Fu T. Value of methylation markers in colorectal cancer (Review). Oncol Rep. 2021;46(2):177. https://doi.org/10.3892/or.2021.8128.

Article  CAS  PubMed  Google Scholar 

Heiss JA, Brenner H. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting. Clin Epigenetics. 2017;9:24. https://doi.org/10.1186/s13148-017-0322-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedersen SK, Symonds EL, Roy AC, Cornthwaite KJ, LaPointe LC, Young GP. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. Cancer Med. 2023;12(2):1319–29. https://doi.org/10.1002/cam4.5008.

Article  CAS  PubMed  Google Scholar 

Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol. 2018;144(9):1741–50. https://doi.org/10.1007/s00432-018-2701-x.

Article  CAS  PubMed  Google Scholar 

Szigeti KA, Kalmár A, Galamb O, Valcz G, Barták BK, Nagy ZB, Zsigrai S, Felletár I, Patai V, Á, Micsik T, Papp M, Márkus E, Tulassay Z, Igaz P, Takács I, Molnár B,. Global DNA hypomethylation of colorectal tumours detected in tissue and liquid biopsies may be related to decreased methyl-donor content. BMC Cancer. 2022;22(1):605. https://d